EUVIMEDEUVIMED entdecken
Crossref

Efficacy and safety of infliximab on colonic mucosal healing in patients with moderate-to-severe ulcerative colitis

ElhamA Hassan, KhaledF Mohamed, AliA Ismail, HaidiK Ramadan, MadihaM El-Attar

Journal of Current Medical Research and Practice · 2017

DOI: 10.4103/2357-0121.210307 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Current Medical Research and Practice, 2017. Verfasst von ElhamA Hassan und 4 weiteren Autor:innen. Die Arbeit nennt 27 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Infliximab (IFX), a monoclonal anti-tumor necrosis factor-α antibody, is commonly used for the treatment of moderate-to-severe inflammatory bowel diseases. No sufficient data are present for its role in the treatment of ulcerative colitis (UC) in our area. We studied the efficacy and safety profile of IFX in treating patients with refractory UC. Patients and methods This prospective study included 48 adult patients with refractory UC. They received IFX (5 mg/kg) intravenously at weeks 0, 2, and 6 at Farwaniya Hospital, Kuwait, between 2013 and 2016. Patients were followed-up for 12 weeks and re-evaluated for clinical and endoscopic response to therapy.

Results

With the exception of four patients who were excluded from the study because of serious side-effects, 44 patients completed the study. At week 12, clinical remission and colonic mucosal healing were achieved in 29 (65.9%) patients after initiating IFX treatment. Of these 29 responders, no relapse occurred. No serious adverse events or mortalities were recorded during the course of treatment among the studied patients treated with IFX.

Conclusion

IFX is a safe and efficient therapy that may be useful for induction of remission in patients with refractory UC.

Zitieren

APA

Hassan, E., Mohamed, K., Ismail, A., Ramadan, H., & El-Attar, M. (2017). Efficacy and safety of infliximab on colonic mucosal healing in patients with moderate-to-severe ulcerative colitis. Journal of Current Medical Research and Practice. https://doi.org/10.4103/2357-0121.210307

Vancouver

Hassan E, Mohamed K, Ismail A, Ramadan H, El-Attar M. Efficacy and safety of infliximab on colonic mucosal healing in patients with moderate-to-severe ulcerative colitis. Journal of Current Medical Research and Practice. 2017. doi:10.4103/2357-0121.210307

BibTeX
@article{Hassan2017,
  author = {Hassan, ElhamA and Mohamed, KhaledF and Ismail, AliA and Ramadan, HaidiK and El-Attar, MadihaM},
  title = {Efficacy and safety of infliximab on colonic mucosal healing in patients with moderate-to-severe ulcerative colitis},
  journal = {Journal of Current Medical Research and Practice},
  year = {2017},
  doi = {10.4103/2357-0121.210307}
}
Kostenlos starten →